{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:53:20Z","timestamp":1790952800027,"version":"4.1.0"},"reference-count":18,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>There is ambiguity regarding usage of tranexamic acid for melasma in India, be it in its pre-administration evaluation, administration route, dosing or monitoring. Hence, we conducted this study to understand various tranexamic-acid prescribing patterns and provide practical guidelines.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>A Google-form-based questionnaire (25-questions) was prepared based on the key areas identified by experts from the Pigmentary Disorders Society, India and circulated to practicing dermatologists across the country. In rounds 2 and 3, the questionnaire was re-presented to the same group of experts and their opinions were sought. The results of the practitioners\u2019 survey were denoted graphically alongside, to guide them. Consensus was deemed when at least 80% of respondents chose an option.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The members agreed that history pertaining to risk factors for thromboembolism, cardiovascular and menstrual disorders should be sought in patients being started on oral tranexamic-acid. Baseline coagulation profile should be ordered in all patients prior to tranexamic-acid and more exhaustive investigations such as complete blood count, liver function test, protein C and S in patients with high risk of thromboembolism. The preferred oral dose was 250 mg orally twice daily, which can be used alone or in combination with topical hydroquinone, kojic acid and sunscreen. Repeated dosing of tranexamic-acid may be required for those relapsing with melasma following initial tranexamic-acid discontinuation. Coagulation profile should ideally be repeated at three monthly intervals during follow-up, especially in patients with clinically higher risk of thromboembolism. Treatment can be stopped abruptly post improvement and no tapering is required.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Limitation<\/jats:title>\n<jats:p>This study is limited by the fact that open-ended questions were limited to the first general survey round.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Oral tranexamic-acid provides a valuable treatment option for melasma. Frequent courses of therapy may be required to sustain results and a vigilant watch is recommended for hypercoagulable states during the course of therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijdvl_1157_2022","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T08:00:15Z","timestamp":1690185615000},"page":"41-45","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prescribing practices of tranexamic acid for melasma: Delphi consensus from the Pigmentary Disorders Society"],"prefix":"10.25259","volume":"90","author":[{"given":"Rashmi","family":"Sarkar","sequence":"first","affiliation":[{"name":"Department of Dermatology, Lady Hardinge Medical College and Hospitals, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh","family":"Narayan R","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshavamurthy","family":"Vinay","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridhima","family":"Lakhani","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surabhi","family":"Sinha","sequence":"additional","affiliation":[{"name":"Department of Dermatology, PGIMER, Dr. Ram Manohar Lohia Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkataram","family":"Mysore","sequence":"additional","affiliation":[{"name":"Dermatology Section, Venkat Centre for Skin and Plastic Surgery, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthu","family":"Sendhil Kumaran","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mala","family":"Bhalla","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Skin Office, Government Medical College and Hospital, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Dermatology, KPC Medical College and Hospital, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavesh","family":"Swarnkar","sequence":"additional","affiliation":[{"name":"Dermatology Section, Swarnkar Superspeciality Center, Indore, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devinder","family":"Mohan Thappa","sequence":"additional","affiliation":[{"name":"Department of Dermatology and STD, JIPMER, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrashis","family":"Podder","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Ojha Sharma","sequence":"additional","affiliation":[{"name":"Dermatology Section, Twacha Skin Clinic, Road Opposite Bal Bharti School, Dwarka, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Kumar Somani","sequence":"additional","affiliation":[{"name":"Dermatology Section, Dermatrendz, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamanta","family":"Barua","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Assam Medical College & Hospital, Dibrugarh, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Jagadeesan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amrita Institute of Medical Sciences, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Dogra","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"10.25259\/IJDVL_1157_2022\/ref-1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/jdv.15987","article-title":"Psychological disturbances in patients with pigmentary disorders: a cross-sectional study","volume":"34","author":"Dabas","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_1157_2022\/ref-2","first-page":"3219","article-title":"Treatment of melasma with tranexamic acid","volume":"13","author":"Nijo","year":"1979","journal-title":"The Clin Rep"},{"key":"10.25259\/IJDVL_1157_2022\/ref-3","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12465","article-title":"Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies","volume":"30","author":"Taraz","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_1157_2022\/ref-4","doi-asserted-by":"publisher","first-page":"e12704","DOI":"10.1111\/dth.12704","article-title":"Efficacy of oral tranexemic acid in refractory melasma: A clinico-immuno-histopathological study","volume":"31","author":"Nagaraju","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_1157_2022\/ref-5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/DSS.0000000000003423","article-title":"Tranexamic Acid Microinjection Alone Versus Its Combination With Fractional Carbon Dioxide Laser in Melasma Treatment: A Dermoscopic Evaluation","volume":"48","author":"Tawfic","year":"2022","journal-title":"Dermatol Surg"},{"key":"10.25259\/IJDVL_1157_2022\/ref-6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.2340\/00015555-2668","article-title":"Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review","volume":"97","author":"Kim","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.25259\/IJDVL_1157_2022\/ref-7","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1468-3083.2012.04464.x","article-title":"Effect of tranexamic acid on melasma: a clinical trial with histological evaluation","volume":"27","author":"Na","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_1157_2022\/ref-8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jdermsci.2017.05.019","article-title":"Tranexamic acid inhibits melanogenesis by activating the autophagy system in cultured melanoma cells","volume":"88","author":"Cho","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.25259\/IJDVL_1157_2022\/ref-9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jaad.2016.03.001","article-title":"Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis","volume":"75","author":"Lee","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1157_2022\/ref-10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/ejh.13348","article-title":"The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients","volume":"104","author":"Cai","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.25259\/IJDVL_1157_2022\/ref-11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.25259\/IJDVL_530_2021","article-title":"The optimal dose of oral tranexamic acid in melasma: A network meta-analysis","volume":"89","author":"Wang","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_1157_2022\/ref-12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jaad.2017.09.053","article-title":"Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma","volume":"78","author":"Del Rosario","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1157_2022\/ref-13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/ijdd.ijdd_37_17","article-title":"Tranexamic acid in melasma: Why and how?","volume":"3","author":"Dashore","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"10.25259\/IJDVL_1157_2022\/ref-14","doi-asserted-by":"crossref","DOI":"10.1111\/jocd.15305","article-title":"Evaluation of oral tranexamic acid as a novel treatment for melasma with a high benefit-risk ratio","author":"Simpson","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"10.25259\/IJDVL_1157_2022\/ref-15","doi-asserted-by":"crossref","first-page":"AB126","DOI":"10.1016\/j.jaad.2022.06.537","article-title":"33031 Use of topical tranexamic acid in patients with melasma: A narrative review","volume":"87","author":"Thieman","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1157_2022\/ref-16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4103\/0019-5154.164416","article-title":"Oral Tranexamic Acid with Fluocinolone-Based Triple Combination Cream Versus Fluocinolone-Based Triple Combination Cream Alone in Melasma: An Open Labeled Randomized Comparative Trial","volume":"60","author":"Padhi","year":"2015","journal-title":"Indian J Dermatol"},{"key":"10.25259\/IJDVL_1157_2022\/ref-17","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1080\/09546634.2020.1781755","article-title":"Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma","volume":"33","author":"Gamea","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.25259\/IJDVL_1157_2022\/ref-18","doi-asserted-by":"publisher","first-page":"502","DOI":"10.29271\/jcpsp.2019.06.502","article-title":"Combination of Oral Tranexamic Acid with Topical 3% Tranexamic Acid versus Oral Tranexamic Acid with Topical 20% Azelaic Acid in the Treatment of Melasma","volume":"29","author":"Malik","year":"2019","journal-title":"J Coll Physicians Surg Pak"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/prescribing-practices-of-tranexamic-acid-for-melasma-delphi-consensus-from-the-pigmentary-disorders-society\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/prescribing-practices-of-tranexamic-acid-for-melasma-delphi-consensus-from-the-pigmentary-disorders-society\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T20:10:03Z","timestamp":1703448603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/prescribing-practices-of-tranexamic-acid-for-melasma-delphi-consensus-from-the-pigmentary-disorders-society\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":18,"alternative-id":["10.25259\/IJDVL_1157_2022"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_1157_2022","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"article-number":"41"}}